Thursday, July 06, 2006

Epeius Biotechnologies Initiates Tri-REX Vaccination Protocols For Breast Cancer

Epeius Biotechnologies today announced the opening of a Vaccine-assisted Phase I/II clinical trial for metastatic breast cancer that is refractory to conventional chemotherapy. The innovative protocol introduces Reximmune-C(TM), the second in a series of targeted biologic therapies designed to seek out, accumulate in, and destroy metastatic tumor nodules, while sparing normal cells and tissues. The lead product, Rexin-G(TM), has recently been granted Orphan Drug Status by the FDA. --Click the title of this post to read the full article from its source--


Post a Comment

<< Home

/* WebRing Code */